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Structure, function and disease relevance of Wnt inhibitory factor 1, a
secreted protein controlling the Wnt and hedgehog pathways
Krisztina Kerekes, Laszlo Banyai, Maria Trexler and Laszlo Patthy
Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary
ABSTRACT
Wnts and Hedgehogs (Hh) are large, lipid-modified extracellular morphogens that play key roles
in embryonic development and stem cell proliferation of Metazoa. Both morphogens signal
through heptahelical Frizzled-type receptors of the G-Protein Coupled Receptor family and there
are several other similarities that suggest a common evolutionary origin of the Hh and Wnt
pathways. There is evidence that the secreted protein, Wnt inhibitory factor 1 (WIF1) modulates
the activity of both Wnts and Hhs and may thus contribute to the intertwining of these path-
ways. In this article, we review the structure, evolution, molecular interactions and functions of
WIF1 with major emphasis on its role in carcinogenesis.
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Introduction
Cell proliferation of embryonic and adult tissues of
animals is controlled by diverse signaling pathways
including the Notch, epidermal growth factor (EGF),
transforming growth factor b (TGFb), Hedgehog
(Hh) and Wnt pathways. Thanks to recent advances
in comparative genomics and phylogenomics it has
become clear that the Wnt and Hh signaling pathways
are evolutionarily related and that Wnt inhibitory fac-
tor 1 (WIF1) may have a role in the control of both
the Wnt and Hh signaling.
The Wnt signaling pathways
Wnt signaling plays essential roles in the control of
cell proliferation, aberrant activation of Wnt signaling
is responsible for the development of several types of
cancer. Wnts exert their effects through the activation
of three distinct but interconnected signaling path-
ways (Boutros et al. 1998; Kestler and K€uhl 2008;
Nusse et al. 2008; van Amerongen, Mikels, and Nusse
2008; van Amerongen and Nusse 2009; Clark, Nourse,
and Cooper 2012).
The canonical Wnt/b-catenin pathway, the non-
canonical Wnt/planar cell polarity (PCP) and Wnt/
calcium pathways have been shown to mediate signal-
ing through interaction of Wnts with heptahelical
Frizzled-type receptors. Disheveled proteins play a
central role both in canonical and non-canonical Wnt
signaling: by binding to the cytoplasmic C-terminal
tails of Frizzled receptors they transduce the Wnt sig-
nal to down-stream effectors (Figure 1).
Canonical Wnt signals are transmitted through
Frizzled receptors which form co-receptor complexes
with the low-density lipoprotein receptor related pro-
teins 5/6 (LRP5/6) (Figure 1(A)). The key player of
the canonical Wnt signaling pathway is b-catenin. In
the absence of a Wnt stimulus the transcriptional
coactivator b-catenin is degraded by a multiprotein
destruction complex that includes axin, adenomatous
polyposis coli (APC), the Ser/Thr kinases glycogen
synthase kinase 3b (GSK3b) and casein kinase 1
(CK1) and the ubiquitin ligase b-TrCP. b-Catenin is
phosphorylated by GSK3b and CK1, subsequently
ubiquitinated and degraded in the proteasomes
(Stamos and Weis 2013). Binding of Wnt proteins to
Frizzled-Lrp5/6 receptor complexes leads to GSK3b
inactivation, resulting in the release of unphosphory-
lated b-catenin from the multiprotein destruction
complex, b-catenin is then translocated into the
nucleus where it binds to the transcription factor,
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T-cell factor/lymphoid enhancer-binding factor (TCF/
LEF) and induces the expression of Wnt target genes.
In the case of the Wnt/calcium pathway
(Figure 1(B)), binding of Wnts to Frizzled receptors
leads to an increase in intracellular calcium concentra-
tion and activation of calmodulin-dependent protein
kinase type 2 (CamK2). In the Wnt/ PCP pathway,
Wnt activation of receptor complexes containing
Vang-like transmembrane proteins (Vangl), Cadherin
Egf Lag Seven-pass G-type Receptor 1 (Celsr) and tyro-
sine kinase 7 (PTK7) leads to activation of Rac/Rho
GTPases and subsequently to activation of kinases such
as c-jun N-terminal kinase (JNK), promoting cytoskel-
eton remodeling (Figure 1(C)).
Frizzled-type receptors, however, are not the only
membrane proteins that bind Wnts. Domains closely
related to the ligand-binding Fz domain of Frizzled
receptors have been identified in Ror- and MuSK-
type receptor tyrosine kinases (Masiakowski and
Yancopoulos 1998; Saldanha, Singh, and Mahadevan
1998; Xu and Nusse 1998) and these receptor tyrosine
kinases were also found to modulate Wnt signaling
cascades (Hikasa et al. 2002; Oishi et al. 2003; Green,
Kuntz, and Sternberg 2008; Burden, Yumoto, and
Figure 1. Frizzled-dependent Wnt signaling pathways. Wnt ligands transduce their signal through three Frizzled-dependent path-
ways: the canonical Wnt/b-catenin pathway, the non-canonical Wnt/calcium and Wnt/planar cell polarity pathways. Disheveled
proteins (Dvl) play a central role both in canonical and non-canonical Wnt signaling. (A) The canonical pathway requires the co-
receptor LRP5/6. In the absence of a Wnt stimulus, the transcriptional coactivator b-catenin is phosphorylated by a multiprotein
complex composed of adenomatous polyposis coli (APC), axin, glycogen synthase kinase 3b (GSK3b) and casein kinase 1 (CK1),
modified by the ubiquitin ligase b-TrCP and subsequently degraded in the proteasomes. Wnt binding leads to the accumulation
of unphosphorylated b-catenin that can enter the nucleus and together with the transcription factor TCF/LEF induces the expres-
sion of Wnt target genes. (B) In the calcium pathway binding of Wnt to Frizzled results in activation of phospholipase C (PLC),
leading to an increase of cytosolic calcium (Ca2þ) concentration and the subsequent activation of calcium-dependent kinase 2
(CamK2). (C) In the PCP pathway, activation of the receptor complexes containing Frizzled and transmembrane proteins Vangl,
Celsr and PTK7 lead to activation of RacGTPases (Rac) and JNK1, promoting cytoskeleton remodeling.
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Zhang 2013; Martinez et al. 2015; Stricker,
Rauschenberger, and Schambony 2017; Roy, Halford,
and Stacker 2018). Inactive tyrosine-protein kinase 7,
a receptor tyrosine kinase with an extracellular region
composed of seven immunoglobulin-like domains,
has also been shown to bind Wnts (Peradziryi
et al. 2011).
Furthermore, the extracellular part of receptor
tyrosine kinases of the Ryk family was shown to con-
tain a domain related to the WIF domain of WIF1
(Patthy 2000) and these receptor tyrosine kinases
were also shown to be involved in Wnt-binding
(Yoshikawa et al. 2003; Lu et al. 2004; Inoue et al.
2004; Cadigan and Liu 2006; Green, Nusse, and van
Amerongen 2014; Roy, Halford, and Stacker 2018).
The tyrosine kinase domains of the Wnt-binding
Ryk-, Ror- and PTK7 receptor tyrosine kinases, how-
ever, deviate from the consensus tyrosine kinase
sequence. They have atypical amino acid residues at
multiple sites essential for kinase activity, therefore,
they are predicted to be pseudokinases (Hovens et al.
1992; Stacker et al. 1993; Yoshikawa et al. 2001;
Mendrola et al. 2013; Murphy et al. 2014). In the
absence of kinase activity, the Wnt-binding receptor
pseudokinases may function as co-receptors or com-
petitive inhibitors of Frizzled receptor-mediated Wnt
signaling. Interestingly, Ryk undergoes sequential pro-
teolytic cleavage to release the extracellular region
into the extracellular space. A metalloprotease cleaves
between the WIF domain and transmembrane helix
in the Ryk extracellular region to shed the extracellu-
lar Wnt-binding WIF domain (Halford et al. 2013).
The shedding of the extracellular WIF domain of Ryk
raises the possibility of a Wnt sequestration role: these
soluble fragments may bind Wnts to prevent them
from stimulating membrane-bound receptors (Roy,
Halford, and Stacker 2018).
The activity of Wnts is regulated by a variety of
secreted extracellular proteins that interfere with the
formation of the Wnt-receptor complexes. Members of
the Dickkopf family bind to LRP5/6 and prevent asso-
ciation of the receptor with Wnt, whereas Cerberus,
WIF1 and members of the secreted frizzled-related
protein (SFRP) family bind directly to Wnts and pre-
vent their binding to the receptor complex (Kawano
and Kypta 2003; Filipovich et al. 2011; Cruciat and
Niehrs 2013; Malinauskas and Jones 2014).
Wnt signaling is also modulated by a variety of
other proteins that may act as Wnt inhibitors and
activators (Malinauskas and Jones 2014). Prominent
among these are heparan sulfate proteoglycans, such
as glypicans (Yan and Lin 2009; Yan et al. 2009).
The key importance of the canonical Wnt/b-cate-
nin pathway in stem cell control may be illustrated by
the fact that mutations that inactivate the tumor sup-
pressors APC and axin or activate b-catenin, resulting
in constitutive activation of the Wnt signaling path-
way, are among the most frequent causes of carcino-
genesis (Zhan, Rindtorff, and Boutros 2017). The
genes for these proteins (APC, AXIN1 and CTNNB1)
are included in the list of the 125 most important
genes whose mutation drives carcinogenesis
(Vogelstein et al. 2013). Additional genes of the Wnt
pathways (e.g. BTRC, DKK3, DKK4, LEF1, PTK7,
ROR1, ROR2, RYK, SFRP4 and WIF1) are included in
the Cancer Gene Census (Sondka et al. 2018, https://
cancer.sanger.ac.uk/census) and/or in the list of can-
cer genes (Candidate Cancer Gene Database, Abbott
et al. 2015, http://ccgd-starrlab.oit.umn.edu/about.
php) identified by forward genetic screens in mice
(see Supplementary Table S1).
Furthermore, the crucial importance of the canon-
ical Wnt/b-catenin pathway in carcinogenesis is
underlined by the fact that epigenetic changes (DNA
methylation, histone modification and interference by
noncoding RNAs) of practically all key protein com-
ponents of the canonical Wnt signaling pathway
(Wnt ligands, Frizzled receptors, LRP5/6, Dickkopfs,
SFRPs, WIF1, b-catenin, axin, APC, casein kinase 1,
TCF/LEF transcription factor) have been associated
with cancer initiation and progression (Wils and
Bijlsma 2018). The importance of Wnt-antagonists in
the control of cell proliferation may be illustrated by
the fact that epigenetic silencing of the genes for
WIF1, SFRPs and Dickkopf proteins is associated
with aberrant activation of the Wnt-b-catenin path-
way in a variety of cancers, whereas restoration of
their expression inhibits tumor progression
(Filipovich et al. 2011).
The hedgehog signaling pathways
Hh signaling is also essential for the control of cell
proliferation in embryonic and adult tissues and aber-
rant Hh signaling activity may also lead to the devel-
opment of cancers. Hhs also exert their effects
through the activation of several different intracellular
signal transduction pathways (Figure 2).
In the canonical smoothened-dependent signaling
pathway (Figure 2(A)), Hh regulates the activity of
GLI transcription factors. In this pathway, in the
absence of an Hh ligand, Patched (PTCH), a 12-pass
transmembrane Hh receptor, inhibits the activity of
the 7-pass transmembrane protein Smoothened
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(SMO), blocking the signaling activity of the pathway.
In this inactive state full-length GLI is modified by
protein kinase A (PKA), GSK3b, CK1 and by the ubi-
quitin ligase b-TrCP and is subsequently cleaved into
the transcriptional repressor form, GLIR. The repres-
sor form GLIR translocates to the nucleus and inhib-
its the expression of Hh target genes. Binding of Hh
to PTCH relieves the inhibition of SMO and as a
Figure 2. Smoothened-dependent Hh signaling pathways. Hh ligands transduce their signal through three Smoothened-depend-
ent pathways: the canonical pathway, the non-canonical Hh/calcium and Hh/RhoAGTPase signaling pathways. (A) In the canonical
Smoothened-dependent pathway signaling is mediated by the GLI zinc finger transcription factors. In the absence of the Hh lig-
and, the 12 transmembrane Hh receptor Patched (PTCH) inhibits the function of the 7 transmembrane protein Smoothened
(SMO). In this inactive state full-length GLI is modified by protein kinase A (PKA), glycogen synthase kinase-3b (GSK3b), casein kin-
ase 1 (CK1) and by the ubiquitin ligase b-TrCP and is subsequently cleaved into the transcriptional repressor form, GLIR. The
repressor form GLIR translocates to the nucleus and inhibits the expression of Hh target genes. Binding of Hh to Patched (PTCH)
relieves the inhibition of Smoothened (SMO) and as a result of the activity of SMO full-length GLI bypasses the phosphorylation
by PKA, GSK3b and CK1, leading to the formation of activated GLI (GLIA). Activity of SMO also results in the inhibition of
Suppressor of fused homolog (SUFU), the suppressor of GLIA, permitting the formation of GLIA. GLIA then translocates to the
nucleus where it induces the expression of Hh target genes. (B) In the non-canonical Hh/Calcium pathway binding of ligand to
SMO results in activation of phospholipase C (PLC), leading to an increase of cytosolic calcium (Ca2þ) concentration and the sub-
sequent activation of calcium-dependent kinase 2 (CamK2). (C) In the non-canonical Hh/RhoAGTPase signaling pathway, Hh signals
through the activity of SMO via the stimulation of Rac1 and RhoAGTPases.
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result of the activity of SMO full-length GLI bypasses
the phosphorylation by PKA, GSK3b and CK1, lead-
ing to the formation of activated GLI (GLIA).
Activity of SMO also results in the inhibition of sup-
pressor of fused homolog (SUFU), the suppressor of
GLIA, permitting the formation of GLIA. GLIA then
translocates to the nucleus where it induces the
expression of Hh target genes (Ingham and
McMahon 2001; Wilson and Chuang 2010; Robbins,
Fei, and Riobo 2012; Briscoe and Therond 2013; Sari
et al. 2018).
There are several GLI-independent non-canonical
Hh signaling cascades that respond to Hh and elicit
cellular responses, ranging from Ca2þ signaling, cyto-
skeletal rearrangement to apoptosis. Some of them are
SMO-dependent others do not require the activity of
this transmembrane protein (Robbins, Fei, and Riobo
2012; Teperino et al. 2012, 2014). In one of the SMO-
dependent non-canonical pathways, SMO activation is
coupled to a rapid Ca2þ influx and subsequent activa-
tion of CamK2 (Figure 2(B)). In another SMO-
dependent, GLI-independent non-canonical Hh
signaling pathway the activity of SMO leads to stimu-
lation of Rac1 and RhoA small GTPases (Polizio et al.
2011) (Figure 2(C)). There is also evidence for a
SMO-independent, GLI-independent Hh signaling
pathway that operates via PTCH and inhibits the acti-
vation of caspase-3 and promotes cell survival by
inactivating the PTCH pro-apoptotic activity
(Chinchilla et al. 2010).
The various Hh signaling pathways are modulated
by interactions of Hh with multiple membrane-associ-
ated protein partners including cell adhesion mol-
ecule-related/down-regulated by oncogenes (CDO),
Brother of CDO (BOC), growth arrest-specific protein
1 (GAS1), Hh interacting protein (HHIP) and glypi-
cans (GPCs) (Beachy et al. 2010). CDO and BOC pro-
teins are single-pass type I transmembrane proteins,
their extracellular parts contain multiple immuno-
globulin and fibronectin type III repeats. Both CDO
and BOC bind Hh proteins and positively regulate
Hh signaling (Tenzen et al. 2006; Yao, Lum, and
Beachy 2006). The GPI-anchored cell surface associ-
ated protein GAS1 also binds and positively regulates
Hh signaling (Allen, Tenzen, and McMahon 2007;
Martinelli and Fan 2007). On the other hand, Hh
interacting protein (HHIP) that binds Hhs with high
affinity, functions as an inhibitor of Hh signaling
(Chuang and McMahon 1999; Chuang, Kawcak, and
McMahon 2003). The heparan sulfate proteoglycans,
glypicans have also been shown to play an important
role in the modulation of the signaling activity of Hhs
(Gallet, Staccini-Lavenant, and Therond 2008;
Capurro et al. 2008; Kim et al. 2011).
Interestingly, the secreted protein Shifted (Shf), the
Drosophila ortholog of vertebrate WIF1, was also
shown to bind and control the distribution and move-
ment of Hh (Glise et al. 2005; Gorfinkiel et al. 2005).
The importance of Hh signaling in the control of
cell proliferation is underlined by the observation that
mutations of SMO and PTCH1 that constitutively
activate Hh signaling are among the major causes of
carcinogenesis (Riobo 2012; Cannonier and Sterling
2015; Wu et al. 2017; Girardi et al. 2019). The genes
of SMO (SMO) and PTCH1 (PTCH1) are included in
the list of genes whose mutation drives carcinogenesis
(Vogelstein et al. 2013). Several other genes of the Hh
pathways (e.g. desert Hh DHH, sonic Hh SHH,
BTRC, GLI1, SUFU) are also included in the Cancer
Gene Census (Sondka et al. 2018, https://cancer.
sanger.ac.uk/census) and/or in the Candidate Cancer
Gene Database (Abbott et al. 2015, http://ccgd-starr-
lab.oit.umn.edu/about.php; see Supplementary
Table S1).
The role of the canonical Hh pathway in cancer
initiation and progression is also supported by the
fact that epigenetic changes of practically all key com-
ponents of this signaling pathway (genes of Hh
ligands, BOC, BTRC, GAS1, GLI1, GLI2, GLI3, HHIP,
PTCH1, SMO and SUFU) have been associated with
carcinogenesis (Wils and Bijlsma 2018).
Similarities of Wnt and hedgehog pathways
suggesting their common evolutionary origin
It has been pointed out previously that there are sev-
eral similarities of the Hh and Wnt pathways that
suggest their common evolutionary origin (Kalderon
2002; Nusse 2003).
The features they share include the use of GSK3b,
CK1 and the ubiquitin ligase b-TrCP to regulate the
proteolysis of the key transcriptional effectors of their
canonical pathways (b-catenin in the Wnt pathway,
GLI in the Hh pathway, see Figures 1(A) and 2(A)).
SUFU, originally identified as a protein that binds
to GLI and antagonizes its activity in the canonical
Hh pathway, was also found to bind to b-catenin,
export it from the nucleus thereby negatively regulat-
ing b-catenin-dependent transcription (Meng et al.
2001). Thus, there is evidence that SUFU may act as
a common regulator of both the Hh and Wnt path-
ways and contribute to intertwining the two canonical
pathways (Taylor et al. 2004; Min et al. 2011).
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Recent studies suggest that there is also some simi-
larity of the non-canonical Frizzled-Wnt and the non-
canonical SMO-dependent Hh cascades in that both
the Wnt/calcium and the Hh/calcium pathways mediate
Ca2þ influx and subsequent activation of CamK2 (see
Figures 1(B) and 2(B)). The similarity of Hh and Wnt
signaling also holds for the cascades in which activation
of Frizzled or SMO leads to stimulation of Rac and
RhoA small GTPases, resulting in rearrangements of
the cytoskeleton (see Figures 1(C) and 2(C)).
A further similarity of the Hh and Wnt pathways
is that both Hhs and Wnts are lipid-modified and
that the lipid modification of these morphogens is
crucial for their signaling activity.
Wnts and Hhs are palmitoleoylated and palmitoy-
lated by porcupine and Hh acyltransferase, respect-
ively; both enzymes are members of the membrane
bound O-acyltransferase (MBOAT) family (Buglino
and Resh 2012). Wnt proteins are palmitoleoylated in
their N-terminal parts and this modification is essen-
tial for the signaling activity of these morphogens
(Willert et al. 2003; Doubravska et al. 2011). Analysis
of the structure of Wnt8 in complex with the ligand
binding cysteine-rich Fz domain of the receptor,
Frizzled-8, has provided an explanation for the
importance of this lipid modification: the ligand-
receptor interaction was found to be dominated by
the palmitoleic acid side-chain of Wnt8 that is
inserted into a deep groove of the ligand-binding Fz
domain of the receptor (Janda et al. 2012; Figures
3(A) and 4(A)).
The precursors of Hh proteins are modified by pal-
mitic acid at the very N-terminal end of the proteins
after their signal sequence has been removed. The C-
terminal protease domain of the Hh precursor cleaves
the precursor in an autocatalytic manner to release
the active N-terminal signaling domain and during
this cleavage, the C-terminus of the signaling domain
becomes covalently modified by a cholesterol mol-
ecule (Porter et al. 1996; Porter, Young, and Beachy
1996; Pepinsky et al. 1998).
N-terminal palmitoylation of Hh proteins is indis-
pensable for their signaling activity: fatty-acylated Hh
is far more active than the unacylated ligand, blocking
Hh palmitoylation blocks Hh signaling (Williams
et al. 1999; Kohtz et al. 2001; Petrova et al. 2013;
Tukachinsky et al. 2016). Recent studies on “native”
palmitoylated Hh (i.e. the ligand that has both a C-
terminal cholesterol and an N-terminal fatty-acid
modification) in complex with its receptor, PTCH1,
have provided an explanation for the importance of
the palmitoylation of the Hh ligand. These studies
have revealed that the palmitoylated N terminus of
the extended N-terminal part of the ligand inserts
into a cavity between the extracellular domains of
PTCH1 and dominates the receptor-ligand interface
(Qi et al. 2018; Figure 4(B)).
It should be pointed out that, due to their lipida-
tion, Wnts and Hhs are highly hydrophobic, a prop-
erty expected to cause their retention in the plasma
membrane, close to the site of their synthesis.
Nevertheless, Wnts and Hhs can act at both long
Figure 3. Lipid binding sites of the Fz domains of Frizzled and Smoothened receptors. (A) Structure of the Fz domain of Frizzled-
8 in complex with the palmitoleic acid side-chain of Wnt8 ligand (4f0a.pdb). The backbone structure of the Fz domain is shown
in yellow, the palmitoleic acid side-chain of Wnt8 is highlighted in red. (B) Structure of the Fz domain of Smoothened in complex
with cholesterol ligand (6D35.pdb). The backbone structure of the Fz domain is shown in yellow, the cholesterol ligand is high-
lighted in red.
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and short range to control growth and patterning
during development raising questions as to the
mechanisms that permit their movement (Panakova
et al. 2005).
The constraints that lipidation imposes on the
solubility and spread of Wnts and Hhs within tissues
suggests that, in order to diffuse and transfer from
secreting to receiving cells, they need to shield their
Figure 4. Complexes of Wnt and Hedgehog with their receptors and with Wnt Inhibitory Factor 1. (A) Structure of Wnt8 in com-
plex with the Fz domain of the receptor, Frizzled-8 (4f0a.pdb). The backbone structure of Wnt is shown in green, the Fz domain
is shown in yellow, the palmitoleic acid side-chain of Wnt8 is highlighted in red. Note that Wnt8 grasps the Fz domain at two dis-
tinct sites and in one of these sites the ligand-receptor interaction is dominated by the palmitoleic acid side-chain of Wnt8. (B)
Structure of hedgehog in complex with its receptor, Patched1 (6d4j.pdb). The backbone structure of Patched1 is shown in gray,
the palmitoylated N-terminal domain of Hedgehog is shown in magenta, the palmitoyl moiety is highlighted in red. Note that
that the palmitoylated N terminus of the extended N-terminal part of the ligand inserts into a cavity between the extracellular
domains of Patched1. (C) Model of the complex formed by interaction of Wnt (4f0a.pdb) with the WIF domain of Wnt Inhibitory
factor 1 (2ygn.pdb). The backbone structure of palmitoleoylated Wnt is shown in green, the WIF domain is shown in blue. Note
that in this model the palmitoleic acid moiety of Wnt (highlighted in red) inserts into the alkyl-binding site of the WIF domain of
Wnt Inhibitory factor 1. (D) Model of the complex formed by interaction of the palmitoylated N-terminal domain of Hedgehog
(6d4j.pdb) with the WIF domain of Wnt Inhibitory factor 1(2ygn.pdb). The backbone structure of the N-terminal domain of
Hedgehog is shown in magenta, the WIF domain is shown in blue. Note that in this model the palmitoyl moiety of Hh (high-
lighted in red) inserts into the alkyl-binding site of the WIF domain of Wnt Inhibitory factor 1.
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lipid moiety. Several models have been proposed: one
possibility is that they travel on lipoprotein particles.
In harmony with this model, both Wnts and Hhs
were found to copurify with lipoprotein particles, sug-
gesting that they may act as vehicles for the move-
ment of lipid-linked morphogens (Panakova et al.
2005; Langton, Kakugawa, and Vincent 2016).
Wnts and Hhs may be rendered soluble and mobile
in the extracellular space by forming complexes with
Wnt- and Hh-binding proteins. For example, the
secreted Wnt-interacting molecule Swim facilitates
Wnt diffusion through the extracellular matrix and
promotes long-range Wnt signaling by maintaining the
solubility of Wnt (Mulligan et al. 2012).
Recent studies have provided some insight as to
how interactions of Hhs may aid their transport from
secreting to receiving cells (Hall, Cleverdon, and
Ogden 2019). The transporter-like protein Dispatched
(Disp) serves to mobilize Hh ligands to travel toward
distant cellular targets. In the absence of Disp func-
tion, Hhs fail to release from signal-producing cells;
although juxtacrine signaling to cells directly adjacent
to a Hhs source is maintained without Disp, long-
range targets do not receive ligand.
Disp is a homolog of the Hh receptor PTCH; they
are both members of a family of bacterial efflux
pumps. These proteins have a characteristic topology
with 12 transmembrane domains, arranged in two
halves each containing six transmembrane helices and
one large extracellular globular domain (see PTCH in
Figure 2). Based on the homology of Disp and PTCH,
it is plausible to assume that Hh binds to Disp in a
way similar to that observed in the case of PTCH
(Figure 4(B)). Hh is transferred from the Disp-Hh
complex to the Hh-binding protein secreted protein
Scube2 and/or heparan-sulfate proteoglycans, allowing
the travel of Hh to more distant cellular targets.
A further similarity of the Wnt and Hh pathways
is that heparan-sulfate proteoglycans play a significant
role in the transport of both Wnts and Hh proteins.
Heparan-sulfate proteoglycans are proteins with
branched sugar side chains that are expressed on the
cell surface and form complexes with a variety of sig-
naling molecules, including Wnts and Hhs (Xie and
Li 2019). Glypicans are among the most important
groups of heparan sulfate proteoglycans. These pro-
teins contain an N-terminal a-helical fold followed by
a stalk region that is attached to the outer cell mem-
brane via a glycosylphosphatidyl-inositol anchor. The
stalk regions contain a number of attachment sites for
heparan sulfate chains (Kim et al. 2011). The heparan
sulfate moieties of glypicans play a key role in their
ability to modulate the signaling activity of a wide
variety of heparin-binding growth factors, such as
fibroblast growth factor, Hhs, Wnts and members of
the TGFb families. All these morphogens elicit con-
centration-dependent responses in target cells and
their interaction with heparan sulfate moieties of gly-
picans is required to establish their proper distribu-
tion (Yan and Lin 2009). Recent work, however, has
demonstrated a role for the N-terminal protein
domain that lacks heparan sulfate modifications in
mediating responsiveness to Wnt and Hh signals, the
protein cores may thus mediate functions that are
more specific to particular glypican-morphogen inter-
actions (Capurro et al. 2008; Yan et al. 2009; Williams
et al. 2010; Yan et al. 2010).
Finally, the most striking feature shared by the
Wnt and Hh pathways is that signaling by the ligands
is mediated by closely related heptahelical transmem-
brane receptors (Frizzled and SMO, respectively) that
belong to the same family of G-protein coupled
receptors (GPCRs). GPCRs are usually grouped into 6
classes based on sequence homology and functional
similarity. Frizzled and SMO belong to the F group,
their domain architectures are identical: they have
seven transmembrane helices and an N-terminal extra-
cellular cysteine-rich ligand-binding domain, the Fz
domain. There is now compelling evidence that this
unique domain architecture evolved in Eukaryotes
before the origin of animals (Prabhu and Eichinger
2006; Harwood 2008; Nordstr€om et al. 2011; Krishnan
et al. 2012; Yan et al. 2014).
Despite the structural similarity of the Frizzled and
SMO receptors, their role in morphogen signaling
shows major differences. First, the morphogen pro-
teins initiating signaling of the Wnt and Hh pathways
are unrelated. Studies on the structure of Wnts have
revealed that these large secreted morphogens actually
consist of two distinct structural domains: an N-ter-
minal saposin-related domain and a C-terminal cyst-
ine knot cytokine-related domain (Janda et al. 2012;
Bazan, Janda, and Garcia 2012). Based on these struc-
tural similarities it has been suggested that the com-
mon ancestor of Wnts was formed in Metazoa by
fusion of a saposin-like protein with a cystine-knot
cytokine (Bazan, Janda, and Garcia 2012).
Hh proteins also consist of two domains: an N-ter-
minal ligand domain (the HH-signal domain) that gets
released from the Hh precursor through the action of
the C-terminal intein domain (the Hint domain).
Studies on the evolutionary history of the constituent
domains suggest that the domain architecture
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characteristic of Hhs arose only in Metazoa (Adamska
et al. 2007b; Matus et al. 2008; Roelink 2018).
Another major difference between the two path-
ways is that, whereas Wnt proteins bind to the Fz
domain of Frizzled receptors, SMO receptors are not
thought to interact with Hh proteins or any other
extracellular protein ligand. Hh activates SMO indir-
ectly by binding to PTCH, a 12-transmembrane pro-
tein that inhibits the activity of SMO. As a
consequence of the PTCH-Hh interaction, SMO is
released from the inhibitory activity exerted by PTCH
(McCabe and Leahy 2015; Figure 2).
Nevertheless, recent studies have revealed some
interesting similarities in the activation of Frizzled
and SMO receptors as a consequence of the action of
Wnt and Hh. Frizzled is activated by binding of Wnt
to the extracellular Fz domain of the receptor. As dis-
cussed above, analysis of the structure of Wnt8 in
complex with the Fz domain of Frizzled-8 has
revealed that the two domains (the saposin-like and
cytokine-like domains) of the Wnt morphogen grasp
the Fz domain at two distinct binding sites. The pal-
mitoleic acid side-chain of the N-terminal saposin-
like domain of Wnt8 is inserted into a deep groove of
the Fz domain of the receptor, whereas the C-ter-
minal cytokine-related domain of Wnt8 forms con-
tacts with a site on the opposite side of the Fz
domain (Janda et al. 2012; Figures 3(A) and 4(A)).
SMO is activated by binding of cholesterol to the
extracellular cysteine-rich Fz domain of the receptor.
Recent studies on the crystal structures of SMO have
shown that upon binding of cholesterol to the Fz
domain, the Fz domain undergoes a dramatic reorien-
tation and causes the transmembrane domain to
adopt a conformation similar to active G-protein-
coupled receptors (Huang et al. 2018). Significantly,
the residues involved in binding of sterol ligands by
the Fz domain of SMO are structurally equivalent
with those contacting the Wnt lipid adduct in the
lipid-binding groove of the homologous Fz domains
of Frizzled receptors (Myers et al. 2013; Nachtergaele
et al. 2013; Huang et al. 2018; Figure 3(A,B)).
In view of the common evolutionary origin of
Frizzled and SMO receptors, the structural equiva-
lence of their binding site for lipid-moieties of Wnts
or cholesterol is probably more than a coincidence.
Since Wnts and Hhs arose only in Metazoa (Nichols
et al. 2006; Adamska et al. 2007a; Matus et al. 2008;
Roelink 2018), it is plausible to assume that in lower
eukaryotes the common ancestor of Frizzled and
SMO receptors functioned as lipid- and sterol-sensing
receptors. According to this view, with the divergence
of the Frizzled and SMO families, SMO receptors
retained their specificity for low molecular weight
lipid ligands (such as cholesterol), whereas Frizzled
receptors evolved to bind lipid molecules attached to
the large, newly formed and expanding family of Wnt
proteins. Although the lipid moieties of Wnts retained
a critical role in their interaction with the Fz domain
of Frizzled receptors, their protein–protein interac-
tions with the saposin-like and cytokine-like domains
of Wnts became of increasing importance. It is note-
worthy in this respect that there is a striking asym-
metry in the evolution of the SMO and Frizzled
families in Metazoa. Whereas the Frizzled family
expanded parallel with the expansion of the Wnt fam-
ily, in the majority of Metazoa there is a single SMO
gene (Yan et al. 2014; Schenkelaars et al. 2015).
Recent studies have also provided an insight into
the molecular function of PTCH1 that explains how it
inhibits the activity of SMO. Zhang et al. (2018) have
shown that the structure of the PTCH1 protein shows
striking transmembrane domain similarities to pro-
karyotic transporters. A central hydrophobic conduit
with cholesterol-like contents resembles that used by
other transporters, suggesting that PTCH has choles-
terol transport activity and that PTCH1 inhibits SMO
by controlling the availability of cholesterol for SMO.
According to this model, binding of Hh to PTCH1
blocks its transporter activity, thereby relieving SMO
from the inhibitory control of PTCH1.
Evolution of the Wnt and hedgehog pathways
Comparative genomics of various groups of Metazoa
lend support to the view that key constituents of the
three major Frizzled/SMO-dependent pathways
evolved in early multicellular animals, concurrent
with the evolution of multicellularity.
So far no Wnts or Hhs have been described from
fungi, plants or unicellular eukaryotes, suggesting that
the fusion of their constituent domains occurred in
Metazoa (Adamska et al. 2007b; Bazan, Janda, and
Garcia 2012). Although the Wnt and Hh signaling
pathways appear to be inventions of Metazoa it is
possible to identify some components of these signal-
ing pathways in protozoa (Holstein 2012). Several
Frizzled/SMO-like genes have been described in the
social ameba Dictyostelium discoideum. Sixteen of
these encode cysteine-rich Fz domain, indicating that
the domain architecture typical of Frizzled/SMO
receptors arose prior to the emergence of Metazoa
(Harwood 2008). Orthologs of the Wnt co-receptor
proteins LRP5/6, however, are apparently missing
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from these slime molds (Eichinger et al. 2005; Prabhu
and Eichinger 2006).
Of the main components of the canonical Wnt sig-
nal transduction cascade, GSK3b, CK1 and a protein
related to b-catenin, aardvark, are present in
Dictyostelium, but other key components of the Wnt
signal transduction cascade, such as disheveled, axin
and APC proteins, or orthologs of the TCF/LEF tran-
scription factors have not been found, suggesting that
these are metazoan-specific innovations (Harwood
et al. 1995; Grimson et al. 2000; Coates et al. 2002;
Schilde et al. 2004).
In the case of the simple metazoa, Porifera a basal
set of Wnts, Wnt receptors and cytoplasmic trans-
ducers have been identified. The genome of the
sponge Amphimedon queenslandica was shown to
contain the main components of the canonical Wnt/
b-catenin pathway: besides b-catenin, Frizzled recep-
tor and GSK3b, three Wnt genes and genes for the
coreceptor Lrp5/6, disheveled, axin, APC, transcrip-
tion factor TCF/LEF and SFRPs have been identified
(Adamska et al. 2007a, 2010; Srivastava et al. 2010).
Studies on the sponge Oscarella carmela have also
revealed that it expresses core components of the
Wnt pathway (Wnts, Frizzled receptors, dickkopfs,
b-catenin and disheveled) and the receptor tyrosine
kinase MuSK. These analyses have also provided evi-
dence for components of the Hh pathway (PTCH,
SUFU), suggesting that key elements of both the Wnt
and Hh pathways were in place early in animal evolu-
tion, before the divergence of sponge and eumetazoan
lineages (Nichols et al. 2006). More recent studies on
transcriptomes of eight sponge species belonging to
four classes of porifera (Hexactinellida, Demospongiae,
Homoscleromorpha and Calcarea) have shown that all
sponge classes share an unexpectedly large comple-
ment of genes with other metazoans. Surprisingly,
hexactinellid, calcareous and homoscleromorph
sponges were found to share more genes with bilater-
ians than with nonbilaterian basal metazoans, suggest-
ing loss of genes in the latter groups (Riesgo et al.
2014). Most components of the Hh signaling pathway
were present in all sponge classes. Significantly, there
is a SMO gene that clearly lies within the SMO family
and does not cluster with the closely related Frizzled
genes. The other key components of the pathway,
PTCH, GSK3b, CK1, SUFU, GLI, b-TrCP and HHIP
were all found in the poriferan transcriptomes.
Apparently, most key components of the Wnt signal-
ing pathways are also present: Wnt, Frizzled receptor,
LRP5/6, disheveled, axin, APC, b-catenin, TCF/LEF,
SFRPs, dickkopf and WIF1 were identified in at least
some of the porifera classes. Although earlier studies
on Amphimedon queenslandica have concluded that
genes for constituents of the noncanonical Wnt path-
ways are missing (Adamska et al. 2007a, 2010) more
recent studies on genomes and transcriptomes from
all poriferan lineages confirmed that members of the
PCP pathway, including Vangl and Celsr orthologs
are present in one sponge lineage, suggesting that the
full PCP pathway may have arisen in the last com-
mon ancestor of animals (Schenkelaars et al. 2016).
The genome of the Ctenophore Mnemiopsis leidyi
also contains orthologs of the main components of
Wnt signaling: four Wnt ligands, b-catenin, dishev-
eled, two Frizzled receptors, SFRP, transcription factor
TCF/LEF, LRP5/6, GSK3b, CK1, APC (Pang et al.
2010), but Mnemiopsis leidyi was found to lack most
of the major genes necessary for Hh signaling, such
as a Hh ligand, the SMO receptor and SUFU (Ryan
et al. 2013).
The genome of the placozoan, Trichoplax adhaerens,
was found to have three Wnt genes and genes for
Frizzled receptors, GSK3b, b-catenin, disheveled, axin
and transcription factor TCF/LEF (Srivastava et al.
2008). The Trichoplax genome also contains Vangl and
Celsr orthologs, supporting the existence of a func-
tional PCP pathway (Schenkelaars et al. 2016).
However, Srivastava et al. (2008) did not find evidence
for a functioning Hh pathway in Trichoplax, since
there was no evidence for genes of Hh ligand, PTCH
or SMO receptor, or GLI-like transcription factors.
The genomes of the Cnidarians Nematostella
(Putnam et al. 2007) and Hydra (Chapman et al.
2010) contain members of all bilaterian Wnt gene
subfamilies (Kusserow et al. 2005; Lee et al. 2006;
Lengfeld et al. 2009) that act in the canonical and the
PCP pathways, and all core components of the Wnt
receptor and the b-catenin destruction complex are
present. The number of Frizzled receptors was found
to be lower than that of the ligands, suggesting that
the radiation of Wnt genes was followed by diversifi-
cation of the receptors. Orthologs of proteins involved
in PCP signaling (Vangl, RhoA and RAC1) as well as
components of the Ca2þ signaling pathway (PLC,
PKC, CamK2 and Calcineurin) are also present in
Cnidaria. Furthermore, several secreted Wnt antago-
nists have been identified. e.g. SFRP, WIF, Cerberus
and dickkopf proteins (Technau et al. 2005; Augustin
et al. 2006; Guder, Philipp, et al. 2006, Guder, Pinho,
et al. 2006; Lee et al. 2006; Holstein, Watanabe, and
Ozbek 2011; Technau and Steele 2011). Genomic sur-
veys indicate that Nematostella vectensis possesses
essentially the full repertoire of Hh signaling pathway
38 K. KEREKES ET AL.
components found among bilaterian model organisms
(Matus et al. 2008). These studies on Nematostella
vectensis have identified two typical Hh genes encod-
ing both ligand domain and an autocatalytic intein
domain, a PTCH gene, two SMO genes, genes for two
glypicans, a CDON/BOC/related Hh-binding type I
receptor and orthologs of HHIP and GAS1 which
bind extracellular Hh ligands and regulate their activ-
ity and range of movement. Nematostella vectensis
was also shown to possess genes encoding GLI3 and
core components of the GLI cleavage complex includ-
ing SUFU, two b-TRCPs as well as associated GLI
kinases (PKA, GSK3b and CK1). Conversely, ortho-
logs of WIF1 were apparently missing from
Nematostella vectensis, leading the authors to suggest
that it evolved in bilateria after the divergence of cni-
darians and bilaterians (Matus et al. 2008).
In summary, comparative genomic studies indicate
that key elements of both the Wnt and Hh pathways
were in place early in animal evolution, before the
divergence of sponge and eumetazoan lineages, sug-
gesting that Wnt and Hh signaling diverged at a very
early stage of metazoan evolution.
Evolution of Wnt inhibitory factor 1
Since there is some controversy in the literature as to
the presence or absence of WIF1 proteins in basal
metazoan, we have reexamined the evolutionary his-
tory of this protein.
Hsieh et al. (1999) first characterized WIF1 from
fish, amphibia and mammals as a secreted protein
with an N-terminal WIF domain and five EGF-like
domains (Figure 5(A)). Subsequently, it was shown
that an ortholog of vertebrate WIF1s is also present
in Drosophila (Glise et al. 2005; Gorfinkiel et al.
2005). The domain architecture of the Drosophila Shf
protein is identical with that of vertebrate WIF1
orthologs in as much as it also has an N-terminal
WIF module and five EGF-like domains (Figure
5(A)). In addition to Vertebrates and Arthropods,
WIF domains orthologous with the WIF domains of
WIF1 are also present in Porifera, Cnidaria, Annelida,
Brachiopoda, Mollusca, Echinodermata and
Hemichordata (see Supplementary Table S2 and
Figure 5(A)), indicating that this domain-type was
present prior to the divergence of metazoan phyla. It
is noteworthy that the architecture of the protein
identified in the sponge, Oopsacas minuta, has signifi-
cant similarity to bilaterian WIF1 proteins: it has an
N-terminal WIF domain, three EGF domains and a
C-terminal immunoglobulin domain, suggesting that
WIF domains and EGF domains were fused in the
first Metazoa, to yield the common ancestor of WIF1
proteins (Figure 5(A)).
Cnidaria also have secreted proteins containing
WIF domains orthologous with those of WIF1 pro-
teins, these proteins, however, lack EGF domains.
They have C-terminal NTR domains, a WIF-NTR
domain architecture reminiscent of the Fz-NTR archi-
tecture of SFRPs (see Supplementary Table S2 and
Figure 5(B)).
It should be emphasized that WIF domains dis-
tantly related to those of WIF1 proteins are also pre-
sent in Ryk-type receptor kinases (Patthy 2000).
Proteins with domain architectures characteristic of
Ryk-type receptor kinases are found in Placozoa,
Cnidaria and all groups of Bilateria, but have not
been found in Porifera and Ctenophora (see
Supplementary Table S2 and Figure 5(C)). Since
Placozoa belong to the same clade as Cnidaria and
Bilateria (Ryan et al. 2013) this pattern may suggest
that the domain architecture characteristic of Ryks
was formed in this clade after its divergence from
Porifera and Ctenophora.
Molecular functions of Wnt inhibitory factor 1
Using Wnt-dependent axis induction in early Xenopus
embryos Hsieh et al. (1999) have found that human
WIF1 blocks the activity of Xenopus Wnt8 in a dose-
dependent manner. Importantly, in this assay, the
N-terminal WIF domain of human WIF1 was as
effective as full-length human WIF1, suggesting that
Wnt-binding activity is associated primarily with
this domain.
The molecular function of Drosophila Shf, however,
was found to be strikingly different from that of ver-
tebrate WIF1 proteins. In flies carrying mutations of
the Shf gene, Hh does not accumulate normally and
the range of Hh movement and signaling is strongly
reduced (Glise et al. 2005; Gorfinkiel et al. 2005).
Conversely, Shf had no detectable roles in Wnt signal-
ing: its overexpression did not generate Wnt-related
defects. Furthermore, although overexpression of
human WIF1 inhibits Wnt signaling in Drosophila, it
failed to rescue the shf phenotype, indicating that the
functions of vertebrate and Drosophila WIF1 proteins
diverged significantly (Glise et al. 2005; Gorfinkiel
et al. 2005; Han and Lin 2005).
Shf protein has been shown to be required for the
stability and normal levels of Hh protein and to con-
trol the distribution and diffusion of lipid-modified
Hh in the extracellular matrix of the Hh-producing
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cells (Glise et al. 2005; Gorfinkiel et al. 2005).
Significantly, the authors have demonstrated (Glise
et al. 2005; Gorfinkiel et al. 2005) that Hh proteins
lacking cholesterol- or palmitoyl moieties can diffuse
into nonexpressing cells in the absence of Shf activity,
suggesting that Shf only interacts with dually lipid-
modified Hh and that the Hh–Shf interaction is pri-
marily through the lipid moieties of Hh. Shf was also
shown to interact with heparan sulfate proteoglycans
stabilizing the interaction between Hh and the proteo-
glycans. Drosophila Shf thus serves as an extracellular
proteoglycan-dependent modulator of Hh signaling,
whereas vertebrate WIF1 proteins have been consid-
ered to function only to bind and inhibit the activity
of Wnts.
To investigate which parts of the Drosophila and
human WIF1 proteins are responsible for their Hh
and Wnt specificity, Sanchez-Hernandez et al. (2012)
analyzed the activity of chimeric constructs during
wing development. The authors have shown that
in the domain swap chimeras, the WIF domain con-
fers the specificity for Hh or Wnt morphogen,
whereas the EGF repeats are important for the inter-
action of WIF1 proteins with the extracellular matrix.
Avanesov et al. (2012) have shown that, just as Shf
reinforces interactions between Hh and glypican hep-
aran sulfate proteoglycans, WIF1 strengthens interac-
tions between Wnt and glypicans, modulating the
action of glypicans toward Wnt inhibition. They have
also shown that interaction of glypicans and the glypi-
can-binding EGF-like domains of WIF1 are required
for WIF1’s full Wnt-inhibiting activity. These authors
(Avanesov et al. 2012) have also used chimeric con-
structs of WIF1 and Shf to investigate the structural
basis of the effects of these proteins on Wnt and Hh
signaling. Full Wnt inhibition required the WIF
domain of vertebrate WIF1 and the heparan sulfate
proteoglycan-binding EGF-like domains of either
Figure 5. Domain architectures of proteins containing WIF domains. (A) WIF domains orthologous with the WIF domain of human
Wnt inhibitory factor 1 are present in proteins of Porifera and various Bilaterian phyla. The domain architectures of these proteins
are also similar in that they contain multiple C-terminal EGF domains (for details, see Supplementary Table S2). (B) WIF domains
orthologous with the WIF domains of Wnt inhibitory factor 1 are also present in Cnidaria, these proteins, however, lack EGF
domains and have C-terminal NTR domains. This domain architecture is reminiscent of secreted frizzled related proteins in which
Fz domains are fused to NTR domains (for details, see Supplementary Table S2). (C) WIF domains related to the WIF domains of
Wnt inhibitory factor 1 are present in Ryk-type receptor kinases. Ryk proteins are found in Placozoa, Cnidaria and all groups of
Bilateria (for details, see Supplementary Table S2).
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vertebrate WIF1 or Drosophila Shf. Full promotion of
Hh signaling was found to require both the EGF-like
domains of Shf and the WIF domains of either WIF1
or Shf. The observation that the WIF domain of ver-
tebrate WIF1 can increase the Hh promoting activity
of EGF domains of Shf suggests that it is capable of
interacting with Hh. In fact, full-length vertebrate
WIF1 affected distribution and signaling of Hh in D.
melanogaster, albeit weakly, suggesting a possible role
for WIF1 as a modulator of vertebrate Hh signaling.
These data suggest that whereas the WIF domains
of both Drosophila Shf and vertebrate WIF1 are cap-
able of interacting with Hh, only the WIF domain of
WIF1 has high affinity for Wnt. A possible explan-
ation for this asymmetry in the cross-talk of the two
pathways is that in the case of the interaction of Hh
with WIF domains the interactions are dominated by
the lipid moieties of the morphogen, whereas in
the case of the interaction of Wnts with WIF
domains specific protein-protein interactions are of
greater importance.
There is some further evidence for WIF1-mediated
cross-talk between the Hh and Wnt pathways. It has
been shown that Shf maintains short-range Hh signal-
ing via a mechanism that does not require the pres-
ence of or binding to the Drosophila glypicans Dally
and Dally-like protein (Avanesov and Blair 2013).
These authors have presented evidence that Shf binds
to the CDO/BOC family Hh co-receptors Interference
Hh (Ihog) and Brother of Ihog, suggesting that Shf
regulates short-range Hh signaling through interac-
tions with the receptor complex. They have also
shown that Ihog can increase the Wnt-inhibitory
activity of vertebrate WIF1, raising the possibility that
interactions between WIF1 and vertebrate CDO/BOC
family members may be involved in Hh signaling.
Studies on human WIF1 proteins have provided
some information on the structural basis of the interac-
tions of WIF1 proteins with Wnt, Hh and with glypi-
cans that may explain the functional similarities and
differences of the Drosophila and human WIF1 proteins.
The three-dimensional structure of the WIF
domain of WIF1 was first determined in solution by
NMR spectroscopy (Liepinsh et al. 2006).
Unexpectedly, the detergent (Brij-35) used in the
refolding protocol of recombinant WIF domain was
found to bind tightly via the alkyl chain to a unique
site of the WIF domain, suggesting that this site
serves as a high affinity alkyl-binding site. Since the
activity of Wnts depends on the presence of a palmi-
toleoylated residue in their amino-terminal saposin-
like domain, it was suggested that this alkyl-binding
site of the WIF domain might be involved in
binding Wnts activated by fatty acid modification.
The high affinity of WIF domains for palmitoleoy-
lated residues would also explain the remarkably high
affinity of human WIF1 not only for different mam-
malian Wnts, but also for Wnts from Xenopus
and Drosophila.
The importance of the alkyl-binding site of the
WIF domain for the WIF1-Wnt interaction has been
tested by mutagenesis of the residues of the alkyl-
binding site (Banyai, Kerekes, and Patthy 2012).
These studies have confirmed that the alkyl-binding
site is critical for Wnt-binding: substitution of resi-
dues known to interact with the alkyl-moiety of Brij-
35 has diminished the affinity of the WIF domain for
Wnts. Nevertheless, none of the mutations resulted in
complete elimination of the binding of the WIF
domain to Wnts, suggesting that – in analogy with
the Wnt-Fz interaction – the N-terminal and C-ter-
minal domains of Wnts may bind to the WIF domain
at distinct sites. This hypothesis was tested using the
C-terminal cytokine-like domains of Wnts and argin-
ine-scanning mutagenesis of the WIF domain. The
results of these analyses suggested that, whereas the
N-terminal, lipid-modified saposin-like domains of
Wnts interact with the alkyl-binding site of the WIF
domain, the cytokine-related domains of Wnts bind
to a surface on the opposite side of the WIF domain
(Kerekes, Banyai, and Patthy 2015; Figure 4(C)).
Although the structure of the WIF domain of Shf
or its complex with lipid-modified Hh has not yet
been determined, it seems likely that the palmitoy-
lated N-terminal region of Hh binds to the alkyl-
binding site of the WIF domain in a way similar to
that proposed in the case of the WIF–Wnt complex
(see Figure 4(C,D)). Since the palmitoyl group
attached to the long, extended N-terminal arm of Hh
may be distant from the globular part of the ligand-
binding domain, the relative contribution of protein–
protein interactions may be less significant in the case
of the Hh-WIF interaction than in the case of the
Wnt-WIF interaction. This interpretation would also
explain the observation that the WIF domains of
both Drosophila and vertebrate WIF1 proteins are
capable of binding Hh (with moderate affinity), but
only vertebrate WIF1 proteins bind Wnts with high
affinity (Sanchez-Hernandez et al. 2012; Avanesov
et al. 2012).
Malinauskas et al. (2011) have studied both full-
length WIF1 protein and isolated WIF domain to
map areas involved in Wnt-recognition using bio-
physical, biochemical and cellular assays. Their studies
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also suggest that the putative Wnt-binding site of
WIF1 covers a discontinuous but discrete area of the
WIF domain surface that includes the surface sur-
rounding the alkyl-binding site identified by the NMR
studies. Studies on the WIF1 protein have also impli-
cated the five EGF domains in Wnt binding. The
crystal structure of WIF1 revealed that the EGF
domains are wrapped back, interfacing with the WIF
domain. It has been suggested that EGFs 2-5 of WIF1
contain a heparan sulfate proteoglycan-binding site,
consistent with a model assigning a major role of the
proteoglycan interactions in the localization of WIF1
type proteins within morphogen gradients.
The suggestion that the C-terminal cytokine-like
domains of Wnts bind to a surface of the WIF
domain that is opposite the alkyl-binding site
(Kerekes, Banyai, and Patthy 2015) raises the possibil-
ity that in the ancestor of WIF1 proteins this surface
may have served to bind some members of the cyst-
ine-knot cytokine superfamily. It is noteworthy in this
respect that Surmann-Schmitt et al. (2012) have found
that WIF1 binds the cystine knot domain of connect-
ive tissue growth factor (CTGF) and inhibits CTGF
activity, leading the authors to suggest that the bio-
logical function of WIF1 may not be confined to the
modulation of Wnt signaling but may also include
the regulation of other signaling pathways.
Tumor suppressor function of Wnt inhibitory
factor 1
In order to explore the physiological functions of
WIF1 in vivo, Kansara et al. (2009) have generated
transgenic mice in which the WIF1 coding sequence
was disrupted. Wif1–/– mice were born at the expected
Mendelian ratios and adult mice lacked obvious
phenotype in any tissues in which WIF1 was
expressed. The animals were able to breed success-
fully, however, Wif1–/– mice were found to be more
susceptible to spontaneous and radiation-induced
osteosarcoma than wild type littermates, suggesting a
tumor suppressor role for WIF1.
The significance of WIF1 as a tumor suppressor is
also supported by the work of Wei et al. (2015).
These authors have studied a large family with strong
familial susceptibility to multiple early onset cancers
including prostate, breast, colon and several other
cancers. They have shown that the presence of a vari-
ant in the regulatory region of HNRNPA0 is associ-
ated with elevated cancer incidence in this family and
that a second rare Cys294Phe mutation of WIF1
interacted with the HNRNPA0 variant resulting in
extremely high risk for cancer in carriers of mutations
in both genes.
The Cys294Phe mutation of WIF1 identified in
this family disrupts a conserved disulfide bond of the
fourth EGF domain of the WIF1 protein, yielding a
mutant protein with an unpaired cysteine. The mis-
folded protein is unlikely to fulfill its function as a
negative regulator of various Wnts and this may lead
to aberrant activation of Wnt signaling pathways.
According to this interpretation, it is the inactivation
of WIF1 as a tumor suppressor that predisposes car-
riers of this WIF1 mutation to multiple early
onset cancers.
There is also evidence that rearrangement and loss
of WIF1 gene may contribute to carcinogenesis.
Chromosome rearrangements involving 12q13–15 are
frequent among several tumors, including pleo-
morphic adenomas. The common molecular target for
these aberrations is the HMGA2 gene, but various
fusion partners of HMGA2 have been reported in
tumors. These fusion transcripts yield either truncated
HMGA2 proteins lacking the acidic COOH-terminal
tail, or chimeric forms of HMGA2 proteins in which
the COOH-terminal tail is replaced by distinct ectopic
sequences. WIF1 also maps to this chromosome
region, approximately 700 kb proximal to HMGA2.
Queimado, Lopes, and Reis (2007) were the first to
report the identification of the WIF1 gene as a novel
HMGA2 fusion partner in a salivary gland pleo-
morphic adenoma. The observed HMGA2/WIF1
fusion transcript results in the replacement of the
COOH-terminal tail of HMGA2 with nine amino
acids coded by frame-shifted WIF1 exon 10. In the
pleomorphic adenoma expressing the HMGA2/WIF1
fusion transcript the authors observed upregulation of
HMGA2 and downregulation of WIF1 supporting the
hypothesis that WIF1 is a salivary gland tumor sup-
pressor gene and that WIF1 downregulation might
contribute to the development and/or progression of
pleomorphic adenomas. Persson et al. (2009) studying
salivary gland pleomorphic adenoma have also identi-
fied tumors that had HMGA2-WIF1 gene fusions with
amplification of the fusion oncogene, demonstrating
that WIF1 is a recurrent and frequent fusion partner
of HMGA2 in pleomorphic adenoma. Analysis of the
various chimeric transcripts revealed that none of
them encoded an intact WIF domain therefore the
fusion proteins cannot function as Wnt inhibitors.
Accordingly, the HMGA2-WIF1 fusions observed in
salivary tumors may contribute to carcinogenesis in
two different ways: by converting HMGA2 into a
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fusion oncogene and by depriving the tumor suppres-
sor WIF1 of its Wnt inhibitory activity.
Nevertheless, a survey of the mutation spectrum
of the WIF1 gene in cancer tissues indicates that it
does not qualify as a Mut-driver gene as defined
by Vogelstein et al. (2013). The authors defined
Mut-driver genes as those that contain a sufficient
number and type of driver gene mutations to unam-
biguously distinguish them from other genes, whereas
Epi-driver genes are expressed aberrantly in tumors
but not frequently mutated. Three major epigenetic
mechanisms are known: DNA methylation, histone
modification, and interference by noncoding strands
of RNA (ncR) of different lengths, such as micro-
RNA (miRNA or miR) and long non-coding RNA
(lncR) (Dawson and Kouzarides 2012).
The data compiled in Supplementary Tables S3
and S4 provide ample evidence to indicate that the
WIF1 gene belongs to the category of Epi-driver
genes. Silencing of WIF1 by methylation
(Supplementary Table S3) and targeting of WIF1 by
noncoding RNAs (Supplementary Table S4) contrib-
utes to a large variety of tumors since these epigenetic
mechanisms lead to downregulation of the expression
of the WIF1 gene.
Wnt inhibitory factor 1 as a biomarker and a
therapeutic target
In view of the overwhelming evidence that inactiva-
tion or epigenetic silencing of WIF1 contributes to a
large variety of tumors, there is increasing interest in
the use of WIF1 as an epigenetic biomarker for early
detection, diagnosis, staging and prognosis of cancer,
usually as part of biomarker panels containing other
components of the Wnt pathway (Urakami, Shiina,
Enokida, Kawakami, Kawamoto, et al. 2006, Urakami,
Shiina, Enokida, Hirata, et al. 2006; Qi et al. 2007;
Lee et al. 2009; Yoshino et al. 2009; Zhang et al. 2014,
2016; Garrigou et al. 2016; Guo et al. 2017; Liu et al.
2017; Hu et al. 2018; Beggs et al. 2019). For example,
Urakami and coworkers compared the combined
methylation status of a panel of Wnt antagonist genes
(DKK3, SFRP1, SFRP2, SFRP4, SFRP5 and WIF1) in
renal cell carcinoma and the corresponding normal
renal tissue. The methylation levels of all Wnt antago-
nists were significantly higher in carcinoma than in
normal renal tissue: the multigene methylation score
of this panel of Wnt antagonist genes proved to have
a high sensitivity and specificity as an epigenetic bio-
marker panel for detection of renal cell carcinoma
(Urakami, Shiina, Enokida, Hirata, et al. 2006). In a
recent study, the Enhanced Neoplasia Detection and
Cancer Prevention in Chronic Colitis (ENDCaP-C)
trial has used a multiplex methylation marker panel
(SFRP1, SFRP2, SFRP4, SFRP5, WIF1, TUBB6, SOX7,
APC1A, APC2, MINT1, RUNX3) to compare the
methylation status of these genes in patients with can-
cer, with dysplasia and without neoplasia in order to
test the value of these genes as epigenetic markers to
identify colitis associated cancer. These studies have
shown that for neoplastic mucosa a five marker panel
(SFRP2, SFRP4, WIF1, APC1A and APC2) was accur-
ate in detecting pre-cancerous and invasive neoplasia
and dysplasia (Beggs et al. 2019).
Furthermore, as part of the efforts to develop can-
cer therapies that exploit inhibitors of the Wnt path-
way (Baarsma, K€onigshoff, and Gosens 2013; Anastas
and Moon 2013; Pez et al. 2013), several studies
assessed the possible use of WIF1 as a therapeutic tar-
get in cancer (Kawano and Kypta 2003; Filipovich
et al. 2011; Malinauskas and Jones 2014).
There are two major types of therapeutic
approaches targeting WIF1. One of these aims to
restore expression of the epigenetically silenced WIF1
gene, the other uses recombinant WIF1 protein or
vectors to express recombinant WIF1 protein.
In the case of the first approach, DNA methyl-
transferase inhibitors represent promising new drugs
for cancer therapies. The most widely used DNA
methyltransferase inhibitors include 5-azacytidine, 5-
aza-2’-deoxycytidine, zebularine, procaine, MG98, epi-
gallocatechin-3-gallate and RG108 (Stresemann et al.
2006; Linnekamp et al. 2017).
Several studies have shown that 5-aza-20-deoxycyti-
dine can reverse the hypermethylation of the WIF1
gene and restore its expression (Mazieres et al. 2004;
Taniguchi et al. 2005; Urakami, Shiina, Enokida,
Kawakami, Tokizane, et al. 2006; Qi et al. 2007; Yang
et al. 2010; Wu et al. 2011; Hu, Dai, and Zeng 2013;
Varol et al. 2014; Fotouhi et al. 2014; Huang et al.
2016). Similarly, procaine, procainamide and epigallo-
catechin-3-gallate have been reported to cause deme-
thylation and reactivation of methylation-silenced
WIF1 gene, restore WIF1 expression and downregu-
late the Wnt canonical pathway, suggesting that they
may have a potential use for preventing the develop-
ment of cancer (Gao et al. 2009a, 2009b; Hu, Dai,
and Zeng 2013).
Curcuminoids have also been reported to be poten-
tial hypomethylation agents. The WIF1 promoter
region is efficiently demethylated by treatment with
bisdemethoxycurcumin, restoring expression of epige-
netically silenced WIF1 gene, causing inhibition of
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Wnt signaling (Liu, Yang, Gong, et al. 2011, Liu,
Yang, Zhou, et al. 2011; Xu et al. 2015).
Norcantharidin treatment has also been shown to
promote demethylation and reactivation of the WIF1
gene, leading to downregulation of the canonical Wnt
signaling pathway (Xie et al. 2015, 2016). Recent stud-
ies also suggest that genistein inhibits the cell invasion
and migration of colon cancer cells by inducing
demethylation and recovery of the activity of WIF1
and downregulation of Wnt signaling (Zhu, Ren, and
Tang 2018). Similarly, triptolides, that were shown to
decrease proliferation, migration and invasion of lung
cancer cells, were found to exert their anti-tumor
effects by epigenetic changes restoring WIF1 expres-
sion (Reno et al. 2016; Nardi et al. 2018; Mao
et al. 2018).
The therapeutic use of DNA methyltransferase
inhibitors to restore activity of epigenetically silenced
WIF1 gene, however, has an obvious limitation: their
action is not specific for the WIF1 gene. To overcome
undesirable side effects, several attempts have been
made to test vectors that express recombinant WIF1
protein. The therapeutic potential of this approach
may be illustrated by the work of Lin et al. (2007).
These authors have shown that nonviral gene transfer
of the WIF1 gene with a pcDNA3.1 expression vector
resulted in the downregulation of Wnt signaling and
inhibition of melanoma cell growth.
Treatment of established hepatocellular carcinoma
tumors with adenoviral vectors carrying WIF1 fused
with Fc fragment of human IgG1 also resulted in sig-
nificant inhibition of tumor growth and prolonged
animal survival, indicating that the Wnt antagonist
WIF1-Fc inhibits Wnt signaling and exerts potent
antitumor activity (Hu et al. 2019). The pVAX-WIF1
expression plasmid has been used to explore the anti-
tumor effect of WIF1 on A549 lung cancer cells in
vitro and on A549 subcutaneous xenografts in vivo
(An et al. 2015). These studies have revealed that
transfection with pVAX-WIF1 significantly inhibited
proliferation and promoted apoptosis in A549 cells,
moreover, pVAX-WIF1 significantly inhibited the
tumor growth of the A549 subcutaneous xenograft in
vivo. Rubin et al. (2010) have used the PCDNA3.1-
WIF1 expression plasmid to study the potential tumor
suppressor function of WIF1 in osteosarcoma. These
authors have found that WIF1 overexpression signifi-
cantly decreased tumor growth rate in nude mice and
markedly reduced the number of lung metastasis in
vivo in a mouse model of osteosarcoma.
Huang et al. (2016) have demonstrated that, in
gallbladder cancer, WIF1 generally exhibited low
levels of expression as a result of gene promoter
methylation. Transfection of the GBC-SD gallbladder
cell line with WIF1-expression plasmid resulted in
significant decrease in cell proliferation, invasion and
metastasis. A nude mouse tumor transplantation
experiment showed that the oncogenicity of the GBC-
SD cells expressing WIF1 was substantially lower
compared with that of the untransfected GBC-SD
cells, suggesting that WIF1 may be an effective treat-
ment target for gallbladder cancer.
Kim et al. (2007) have shown that WIF1 is down-
regulated in non-small cell lung cancer. To test the
therapeutic potential of WIF1, lung cancer cell lines
A549 and H460 were transfected with the mammalian
expression vector pcDNA3.1 containing the WIF1
gene and recombinant WIF1 protein was also used to
treat H460 cells. The authors have shown that colony
formation of WIF1-transfected cells was decreased
and recombinant WIF1 protein was also able to
inhibit H460 cell proliferation. Furthermore, WIF1
significantly inhibited the growth of H460 tumor xen-
ografts in nude mice. These data suggest that WIF1 is
able to inhibit lung cancer cell growth both in vitro
and in vivo and argue for the potential use of WIF1
in the treatment of lung cancer.
In human primary glioblastoma multiforme tumors
WIF1 expression is significantly lower than in normal
brain tissue. Transfection of U251 human glioblast-
oma-derived cells with the pcDNA3.1-WIF1 vector
resulted in the inhibition of cell growth, suggesting
that WIF1 is a potent inhibitor of glioblastoma multi-
forme tumors growth (Wu et al. 2012).
Song et al. (2015) have studied six hepatocellular
carcinoma cell lines of HepG2, Hep3B, Huh7, PLC/
PRF/5, SMMC-7721 and MHCC97 and the immortal-
ized human liver cell line THLE-3. They have found
that the expression of WIF1 in hepatocellular carcin-
oma cell lines was lower than that in the normal liver
cell lines, while there was basically no expression of
WIF1 in the highly metastatic cell line MHCC-97 and
moderate expression in HepG2 and SMMC-7721.
Transfection of hepatocellular carcinoma cell lines
HepG2 and SMMC-7721 with the eukaryotic expres-
sion vector pcDNA3.1-WIF1 resulted in a significant
reduction in the viability and invasion ability in the
carcinoma cells, indicating that up-regulation of
WIF1 expression can significantly inhibit the invasion
and metastasis of HepG2 and SMMC-7721 of hepato-
cellular carcinoma cell lines.
Yee et al. (2010) have studied the effect of WIF1
on the growth and cellular invasiveness of a
bone metastatic prostate cancer (PCa) cell line, PC3.
44 K. KEREKES ET AL.
The authors have shown that the WIF1 gene pro-
moter was hypermethylated and its expression was
down-regulated in the majority of PCa cell lines. 5-
Azacytidine induced re-expression of WIF1 or trans-
fection with pcDNA3.1-WIF1 vector significantly
reduced tumor growth in a xenograft mouse model,
suggesting that blocking Wnt signaling in PCa by
WIF1 may represent a novel strategy to reduce meta-
static disease burden in PCa patients.
In summary, there is increasing evidence that
WIF1 is a valuable epigenetic biomarker for the
detection, diagnosis and characterization of various
types of cancer and is a promising therapeutic target
in cancers in which the WIF1 gene is epigeneti-
cally silenced.
Concluding remarks
The fact that proteins with WIF domains orthologous
with those of vertebrate WIF1 proteins are present in
Porifera, Cnidaria and various groups of Bilateria
argues for an ancient Metazoan origin and an import-
ant biological function of these proteins. Very little is
known, however, about the function of these proteins
in basal metazoa since studies on WIF1-related pro-
teins are limited to vertebrates and Drosophila.
Furthermore, these studies have led to some apparent
controversies as to the function of WIF1 proteins:
whereas research on vertebrate WIF1 emphasizes their
role as negative regulators of the Wnt pathway, stud-
ies on the Drosophila ortholog have revealed that it
functions primarily as a positive modulator of the
Hh pathway.
These apparently different functions of vertebrate
and arthropod proteins, however, have a surprisingly
similar structural basis: lipid moieties of both morph-
ogens appear to play a crucial role in their binding
to WIF1 proteins and the stability of both the
Wnt-WIF1 and Hh-WIF1 complexes is reinforced by
interaction with the heparan sulfate proteoglycans,
glypicans. One of the differences distinguishing Wnt-
WIF1-glypican and Hh-WIF1-glypican ternary com-
plexes is that the WIF1-Wnt complex is characterized
by extensive protein-protein interactions, whereas in
the case of the WIF1-Hh complex the contribution of
the protein-protein interactions are probably less
significant.
Future work on WIF1 is needed to elucidate the
contribution of WIF1 proteins to the control of Wnt
and/or the Hh pathways and to decide whether gen-
etic, epigenetic and therapeutic changes in the activity
of human WIF1 protein affect both the Wnt and Hh
pathways. The significance of this work is that it may
help decide whether loss of WIF1 activity promotes
carcinogenesis only through activation of the Wnt-
pathways or perturbations of other pathways also
contribute to carcinogenesis. Another reason why the
characterization of the interaction of WIF1 with Hh
is important is that therapeutic application of WIF1
may have significant, undesirable side effects if WIF1
has important functions distinct from its role as an
antagonist of Wnts.
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